TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre 3 Year Longitudinal Prospective Study to Identify Novel Endpoints and Compare These With Forced Expiratory Volume in 1 Second (FEV1) for Their Ability to Measure and Predict COPD Severity and Its Progression Over Time
Brief Summary: This is a 3 year longitudinal study to identify novel endpoints and compare these with standard measures such as forced expiratory volume in 1 second (FEV1) for their ability to measure and predict COPD (Chronic Obstructive Pulmonary Disease) severity and its progression over time. Control subjects (smokers and never smokers) will be recruited as comparators with the COPD subjects.


Options:
A: Intervention Type: DRUG; Name: Intravenous prednisolone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Oral prednisolone; Assigned to Arm(s): N/A
B: Arm Label: COPD subjects; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Non-smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Intervention Type: OTHER; Name: Novel endpoint determination; Assigned to Arm(s): COPD subjects, Non-smoker controls, Smoker controls
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD9668 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AZD9668; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Aclidinium bromide 200 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 200 μg bid | Arm Label: Aclidininum bromide 400 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 400 μg bid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide 200 μg bid; Assigned to Arm(s): Aclidinium bromide 200 μg bid | Intervention Type: DRUG; Name: Aclidinium bromide 400 μg bid; Assigned to Arm(s): Aclidininum bromide 400 μg bid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre 3 Year Longitudinal Prospective Study to Identify Novel Endpoints and Compare These With Forced Expiratory Volume in 1 Second (FEV1) for Their Ability to Measure and Predict COPD Severity and Its Progression Over Time
Brief Summary: This is a 3 year longitudinal study to identify novel endpoints and compare these with standard measures such as forced expiratory volume in 1 second (FEV1) for their ability to measure and predict COPD (Chronic Obstructive Pulmonary Disease) severity and its progression over time. Control subjects (smokers and never smokers) will be recruited as comparators with the COPD subjects.


Options:
A: Intervention Type: DRUG; Name: Salmeterol 50mcg/ Fluticasone Propionate 500mcg; Assigned to Arm(s): N/A
B: Arm Label: Mg-group; Type: EXPERIMENTAL; Interventions: Drug: Magnesium Sulphate | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Magnesium Sulphate; Assigned to Arm(s): Mg-group
C: Intervention Type: DRUG; Name: Magnesium Sulfate 2 grams; Assigned to Arm(s): N/A
D: Arm Label: COPD subjects; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Non-smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Intervention Type: OTHER; Name: Novel endpoint determination; Assigned to Arm(s): COPD subjects, Non-smoker controls, Smoker controls

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre 3 Year Longitudinal Prospective Study to Identify Novel Endpoints and Compare These With Forced Expiratory Volume in 1 Second (FEV1) for Their Ability to Measure and Predict COPD Severity and Its Progression Over Time
Brief Summary: This is a 3 year longitudinal study to identify novel endpoints and compare these with standard measures such as forced expiratory volume in 1 second (FEV1) for their ability to measure and predict COPD (Chronic Obstructive Pulmonary Disease) severity and its progression over time. Control subjects (smokers and never smokers) will be recruited as comparators with the COPD subjects.


Options:
A: Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin 250 mg | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin 250 mg; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Avelox (Moxifloxacin, BAY12-8039) | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Avelox (Moxifloxacin, BAY12-8039); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 2
C: Arm Label: Moxifloxacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Moxifloxacin | Arm Label: Azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Doxycycline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Doxycycline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Moxifloxacin; Assigned to Arm(s): Moxifloxacin | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Doxycycline; Assigned to Arm(s): Doxycycline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: COPD subjects; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Non-smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Intervention Type: OTHER; Name: Novel endpoint determination; Assigned to Arm(s): COPD subjects, Non-smoker controls, Smoker controls

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre 3 Year Longitudinal Prospective Study to Identify Novel Endpoints and Compare These With Forced Expiratory Volume in 1 Second (FEV1) for Their Ability to Measure and Predict COPD Severity and Its Progression Over Time
Brief Summary: This is a 3 year longitudinal study to identify novel endpoints and compare these with standard measures such as forced expiratory volume in 1 second (FEV1) for their ability to measure and predict COPD (Chronic Obstructive Pulmonary Disease) severity and its progression over time. Control subjects (smokers and never smokers) will be recruited as comparators with the COPD subjects.


Options:
A: Arm Label: Group 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Behavioral: COPD Self-management Education | Intervention Type: BEHAVIORAL; Name: COPD Self-management Education; Assigned to Arm(s): Group 2
B: Arm Label: COPD subjects; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Non-smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Intervention Type: OTHER; Name: Novel endpoint determination; Assigned to Arm(s): COPD subjects, Non-smoker controls, Smoker controls
C: Arm Label: 1 Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2 Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Action plan | Intervention Type: BEHAVIORAL; Name: Action plan; Assigned to Arm(s): 2 Intervention
D: Intervention Type: BEHAVIORAL; Name: Intermediate care package; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre 3 Year Longitudinal Prospective Study to Identify Novel Endpoints and Compare These With Forced Expiratory Volume in 1 Second (FEV1) for Their Ability to Measure and Predict COPD Severity and Its Progression Over Time
Brief Summary: This is a 3 year longitudinal study to identify novel endpoints and compare these with standard measures such as forced expiratory volume in 1 second (FEV1) for their ability to measure and predict COPD (Chronic Obstructive Pulmonary Disease) severity and its progression over time. Control subjects (smokers and never smokers) will be recruited as comparators with the COPD subjects.


Options:
A: Intervention Type: DEVICE; Name: Noninvasive positive pressure ventilation; Assigned to Arm(s): N/A
B: Arm Label: Active Treatment; Type: ACTIVE_COMPARATOR; Interventions: Device: Continuous Positive Airway Pressure (CPAP) Treatment | Arm Label: Sham/Placebo Treatment; Type: PLACEBO_COMPARATOR; Interventions: Device: Sham CPAP device - CPAP device with pressure delivered <1 cm H20 | Intervention Type: DEVICE; Name: Continuous Positive Airway Pressure (CPAP) Treatment; Assigned to Arm(s): Active Treatment | Intervention Type: DEVICE; Name: Sham CPAP device - CPAP device with pressure delivered <1 cm H20; Assigned to Arm(s): Sham/Placebo Treatment
C: Arm Label: COPD subjects; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Non-smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Intervention Type: OTHER; Name: Novel endpoint determination; Assigned to Arm(s): COPD subjects, Non-smoker controls, Smoker controls
D: Arm Label: NPPV group; Type: EXPERIMENTAL; Interventions: Device: ventilators designed for non invasive ventilation | Arm Label: control gorup; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: ventilators designed for non invasive ventilation; Assigned to Arm(s): NPPV group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre 3 Year Longitudinal Prospective Study to Identify Novel Endpoints and Compare These With Forced Expiratory Volume in 1 Second (FEV1) for Their Ability to Measure and Predict COPD Severity and Its Progression Over Time
Brief Summary: This is a 3 year longitudinal study to identify novel endpoints and compare these with standard measures such as forced expiratory volume in 1 second (FEV1) for their ability to measure and predict COPD (Chronic Obstructive Pulmonary Disease) severity and its progression over time. Control subjects (smokers and never smokers) will be recruited as comparators with the COPD subjects.


Options:
A: Arm Label: NHW COPD Participants; Type: N/A; Interventions: N/A | Arm Label: NHW Control Group; Type: N/A; Interventions: N/A | Arm Label: AA COPD Participants; Type: N/A; Interventions: N/A | Arm Label: AA Control Group; Type: N/A; Interventions: N/A
B: Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
C: Arm Label: COPD subjects; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Non-smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Intervention Type: OTHER; Name: Novel endpoint determination; Assigned to Arm(s): COPD subjects, Non-smoker controls, Smoker controls
D: Arm Label: OM-85; Type: EXPERIMENTAL; Interventions: Drug: OM-85 BV | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: OM-85 BV | Intervention Type: DRUG; Name: OM-85 BV; Assigned to Arm(s): OM-85, Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre 3 Year Longitudinal Prospective Study to Identify Novel Endpoints and Compare These With Forced Expiratory Volume in 1 Second (FEV1) for Their Ability to Measure and Predict COPD Severity and Its Progression Over Time
Brief Summary: This is a 3 year longitudinal study to identify novel endpoints and compare these with standard measures such as forced expiratory volume in 1 second (FEV1) for their ability to measure and predict COPD (Chronic Obstructive Pulmonary Disease) severity and its progression over time. Control subjects (smokers and never smokers) will be recruited as comparators with the COPD subjects.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: n-3 PUFA | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: n-3 PUFA; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
B: Arm Label: Atorvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin, Drug: Formoterol | Arm Label: Lactose tablet; Type: PLACEBO_COMPARATOR; Interventions: Drug: Formoterol, Drug: Lactose tablet | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin | Intervention Type: DRUG; Name: Formoterol; Assigned to Arm(s): Atorvastatin, Lactose tablet | Intervention Type: DRUG; Name: Lactose tablet; Assigned to Arm(s): Lactose tablet
C: Arm Label: COPD subjects; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Non-smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Intervention Type: OTHER; Name: Novel endpoint determination; Assigned to Arm(s): COPD subjects, Non-smoker controls, Smoker controls
D: Arm Label: simvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): simvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre 3 Year Longitudinal Prospective Study to Identify Novel Endpoints and Compare These With Forced Expiratory Volume in 1 Second (FEV1) for Their Ability to Measure and Predict COPD Severity and Its Progression Over Time
Brief Summary: This is a 3 year longitudinal study to identify novel endpoints and compare these with standard measures such as forced expiratory volume in 1 second (FEV1) for their ability to measure and predict COPD (Chronic Obstructive Pulmonary Disease) severity and its progression over time. Control subjects (smokers and never smokers) will be recruited as comparators with the COPD subjects.


Options:
A: Arm Label: COPD subjects; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Non-smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Intervention Type: OTHER; Name: Novel endpoint determination; Assigned to Arm(s): COPD subjects, Non-smoker controls, Smoker controls
B: Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
C: Arm Label: Indacaterol 300 μg plus placebo to formoterol; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol, Drug: Placebo to formoterol | Arm Label: Indacaterol 600 μg plus placebo to formoterol; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol, Drug: Placebo to formoterol | Arm Label: Formoterol 12 μg plus placebo to indacaterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol, Drug: Placebo to indacaterol | Arm Label: Placebo to indacaterol plus placebo to formoterol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to indacaterol, Drug: Placebo to formoterol | Intervention Type: DRUG; Name: Indacaterol; Assigned to Arm(s): Indacaterol 300 μg plus placebo to formoterol, Indacaterol 600 μg plus placebo to formoterol | Intervention Type: DRUG; Name: Formoterol; Assigned to Arm(s): Formoterol 12 μg plus placebo to indacaterol | Intervention Type: DRUG; Name: Placebo to indacaterol; Assigned to Arm(s): Formoterol 12 μg plus placebo to indacaterol, Placebo to indacaterol plus placebo to formoterol | Intervention Type: DRUG; Name: Placebo to formoterol; Assigned to Arm(s): Indacaterol 300 μg plus placebo to formoterol, Indacaterol 600 μg plus placebo to formoterol, Placebo to indacaterol plus placebo to formoterol
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD9668 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AZD9668; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre 3 Year Longitudinal Prospective Study to Identify Novel Endpoints and Compare These With Forced Expiratory Volume in 1 Second (FEV1) for Their Ability to Measure and Predict COPD Severity and Its Progression Over Time
Brief Summary: This is a 3 year longitudinal study to identify novel endpoints and compare these with standard measures such as forced expiratory volume in 1 second (FEV1) for their ability to measure and predict COPD (Chronic Obstructive Pulmonary Disease) severity and its progression over time. Control subjects (smokers and never smokers) will be recruited as comparators with the COPD subjects.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Training with e-health product | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Training with e-health product; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Control
B: Arm Label: Telemedicine; Type: EXPERIMENTAL; Interventions: Device: telemedicine program | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: telemedicine program; Assigned to Arm(s): Telemedicine
C: Arm Label: Telemedicine; Type: ACTIVE_COMPARATOR; Interventions: Device: Telemedicine | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Telemedicine; Assigned to Arm(s): Telemedicine
D: Arm Label: COPD subjects; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Non-smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Intervention Type: OTHER; Name: Novel endpoint determination; Assigned to Arm(s): COPD subjects, Non-smoker controls, Smoker controls

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre 3 Year Longitudinal Prospective Study to Identify Novel Endpoints and Compare These With Forced Expiratory Volume in 1 Second (FEV1) for Their Ability to Measure and Predict COPD Severity and Its Progression Over Time
Brief Summary: This is a 3 year longitudinal study to identify novel endpoints and compare these with standard measures such as forced expiratory volume in 1 second (FEV1) for their ability to measure and predict COPD (Chronic Obstructive Pulmonary Disease) severity and its progression over time. Control subjects (smokers and never smokers) will be recruited as comparators with the COPD subjects.


Options:
A: Arm Label: COPD subjects; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Non-smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Intervention Type: OTHER; Name: Novel endpoint determination; Assigned to Arm(s): COPD subjects, Non-smoker controls, Smoker controls
B: Arm Label: mepolizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mepolizumab | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mepolizumab; Assigned to Arm(s): mepolizumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Benralizumab 100 mg; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab 100 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Benralizumab 100 mg; Assigned to Arm(s): Benralizumab 100 mg
D: Arm Label: Benralizumab Arm A; Type: EXPERIMENTAL; Interventions: Drug: Benralizumab Arm A | Arm Label: Benralizumab Arm B; Type: EXPERIMENTAL; Interventions: Drug: Benralizumab Arm B | Arm Label: Benralizumab Arm C; Type: EXPERIMENTAL; Interventions: Drug: Benralizumab Arm C | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Benralizumab Arm A; Assigned to Arm(s): Benralizumab Arm A | Intervention Type: DRUG; Name: Benralizumab Arm B; Assigned to Arm(s): Benralizumab Arm B | Intervention Type: DRUG; Name: Benralizumab Arm C; Assigned to Arm(s): Benralizumab Arm C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre 3 Year Longitudinal Prospective Study to Identify Novel Endpoints and Compare These With Forced Expiratory Volume in 1 Second (FEV1) for Their Ability to Measure and Predict COPD Severity and Its Progression Over Time
Brief Summary: This is a 3 year longitudinal study to identify novel endpoints and compare these with standard measures such as forced expiratory volume in 1 second (FEV1) for their ability to measure and predict COPD (Chronic Obstructive Pulmonary Disease) severity and its progression over time. Control subjects (smokers and never smokers) will be recruited as comparators with the COPD subjects.


Options:
A: Intervention Type: DRUG; Name: fluticasone 500 mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluticasone 500 mcg + salmeterol 50 mcg; Assigned to Arm(s): N/A
B: Arm Label: COPD subjects; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Non-smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Intervention Type: OTHER; Name: Novel endpoint determination; Assigned to Arm(s): COPD subjects, Non-smoker controls, Smoker controls
C: Intervention Type: DRUG; Name: Tiotropium bromide 18mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Fluticasone propionate/ salmeterol combination 50/500mcg; Assigned to Arm(s): N/A
D: Arm Label: Inhaled corticosteroid, Then placebo; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone propionate, Drug: Placebo | Arm Label: Placebo control, Then inhaled corticosteroid; Type: PLACEBO_COMPARATOR; Interventions: Drug: Fluticasone propionate, Drug: Placebo | Intervention Type: DRUG; Name: Fluticasone propionate; Assigned to Arm(s): Inhaled corticosteroid, Then placebo, Placebo control, Then inhaled corticosteroid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Inhaled corticosteroid, Then placebo, Placebo control, Then inhaled corticosteroid

Answer: B